Mechanisms of p53-mediated repression of the human polycystic kidney disease-1 promoter

Biochimica et Biophysica Acta - Gene Regulatory Mechanisms

Volumn 1799, Issue 7, 2010, Pages 502-509

  van Bodegom, Diederik ^a   Roessingh, Wijnand ^a   Pridjian, Andrew ^a   El Dahr, Samir S ^a  

^a TULANE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

Gene transcription; p53; Polycystic kidney disease gene; Promoter

Indexed keywords

BRADYKININ B2 RECEPTOR; CIS ACTING ELEMENT; HISTONE DEACETYLASE; HISTONE DEACETYLASE 1; HISTONE DEACETYLASE 2; POLYCYSTIN 1; PROTEIN P53; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR SIN3; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; BINDING SITE; CHROMATIN IMMUNOPRECIPITATION; CONSENSUS SEQUENCE; CONTROLLED STUDY; ENZYME ACTIVITY; GC RICH SEQUENCE; GEL MOBILITY SHIFT ASSAY; GENE DISRUPTION; GENE EXPRESSION REGULATION; GENE REPRESSION; GENETIC TRANSFECTION; IN VITRO STUDY; KIDNEY COLLECTING TUBULE; KIDNEY MEDULLA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN ANALYSIS; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRANSCRIPTION REGULATION; WESTERN BLOTTING;

ANIMALS; BASE SEQUENCE; BINDING SITES; GENE EXPRESSION REGULATION; HUMANS; MICE; MODELS, GENETIC; MOLECULAR SEQUENCE DATA; MUTAGENESIS; PROMOTER REGIONS, GENETIC; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TRANSCRIPTION, GENETIC; TRPP CATION CHANNELS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 77953592497     PISSN: 18749399     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbagrm.2010.04.001     Document Type: Article

References (33)

1. Sutters M., and Germino G.G. Autosomal dominant polycystic kidney disease: molecular genetics and pathophysiology. J. Lab. Clin. Med. 141 (2003) 91-101
2. Torres V.E., Harris P.C., and Pirson Y. Autosomal dominant polycystic kidney disease. Lancet 369 (2007) 1287-1301
3. Wilson P.D. Polycystic kidney disease. N. Engl. J. Med. 350 (2004) 151-164
4. Zhang Q., Taulman P.D., and Yoder B.K. Cystic kidney disease: all roads lead to the cilium. Physiology (Bethesda) 19 (2004) 225-230
5. Ong A.C., and Harris P.C. Molecular pathogenesis of ADPKD: the polycystin complex gets complex. Kidney Int. 67 (2005) 1234-1247
6. Puri S., Magenheimer B.S., Maser R.L., Ryan E.M., Zien C.A., Walker D.D., Wallace D.P., Hempson S.J., and Calvet J.P. Polycystin-1 activates the calcineurin/NFAT (nuclear factor of activated T-cells) signaling pathway. J. Biol. Chem. 279 (2004) 55455-55464
7. Puri S., Rodova M., Islam M.R., Magenheimer B.S., Maser R.L., and Calvet J.P. Ets factors regulate the polycystic kidney disease-1 promoter. Biochem. Biophys. Res. Commun. 342 (2006) 1005-1013
8. Parnell S.C., Magenheimer B.S., Maser R.L., Zien C.A., Frischauf A.M., and Calvet J.P. Polycystin-1 activation of c-Jun N-terminal kinase and AP-1 is mediated by heterotrimeric G proteins. J. Biol. Chem. 277 (2002) 19566-19572
9. Kim E., Arnould T., Sellin L.K., Benzing T., Fan M.J., Gruning W., Sokol S.Y., Drummond I., and Walz G. The polycystic kidney 1 gene product modulates Wnt signaling. J. Biol. Chem. 274 (1999) 4947-4953
10. Saadi-Kheddouci S., Berrebi D., Romagnolo B., Cluzeaud F., Peuchmaur M., Kahn A., Vandewalle A., and Perret C. Early development of pkd in transgenic mice expressing an activated mutant of the beta-catenin gene. Oncogene 20 (2001) 5972-5981
11. 2+-dependent pathways. Exp. Cell Res. 304 (2005) 391-406
12. Thivierge C., Kurbegovic A., Couillard M., Guillaume R., Cote O., and Trudel M. Overexpression of PKD1 causes polycystic kidney disease. Mol. Cell. Biol. 26 (2006) 1538-1548
13. Guillaume R., D'Agati V., Daoust M., and Trudel M. Murine Pkd1 is a developmentally regulated gene from morula to adulthood: role in tissue condensation and patterning. Dev. Dyn. 214 (1999) 337-348
14. Ward C.J., Turley H., Ong A.C., Comley M., Biddolph S., Chetty R., Ratcliffe P.J., Gattner K., and Harris P.C. Polycystin, the polycystic kidney disease 1 protein, is expressed by epithelial cells in fetal, adult, and polycystic kidney. Proc. Natl. Acad. Sci. U. S. A. 93 (1996) 1524-1528
15. Pritchard L., Sloane-Stanley J.A., Sharpe J.A., Aspinwall R., Lu W., Buckle V., Strmecki L., Walker D., Ward C.J., Alpers C.E., Zhou J., Wood W.G., and Harris P.C. A human PKD1 transgene generates functional polycystin-1 in mice and is associated with a cystic phenotype. Hum. Mol. Genet. 9 (2000) 2617-2627
16. Lantinga-van Leeuwen I.S., Leonhard W.N., Dauwerse H., Baelde H.J., van Oost B.A., Breuning M.H., and Peters D.J. Common regulatory elements in the polycystic kidney disease. Eur. J. Hum. Genet. 13 (2005) 649-659
17. Rodova M., Islam M.R., Maser R.L., and Calvet J.P. The polycystic kidney disease-1 promoter is a target of the bta catenin/T-cell factor pathway. J. Biol. Chem. 277 (2002) 29577-29583
18. Jeon J.O., Yoo K.H., and Park J.H. Expression of the Pkd1 gene is momentously regulated by Sp1. Nephron. Exp. Nephrol. 107 (2007) e57-e64
19. Islam M.R., Puri S., Rodova M., Magenheimer B.S., Maser R.L., and Calvet J.P. Retinoic acid-dependent activation of the polycystic kidney disease-1 (PKD1) promoter. Am. J. Physiol. Renal. Physiol. 295 (2008) F1845-F1854
20. Van Bodegom D., Saifudeen Z., Dipp S., Puri S., Magenheimer B.S., Calvet J.P., and El-Dahr S.S. The polycystic kidney disease-1 gene is a target for p53-mediated transcriptional repression. J. Biol. Chem. 281 (2006) 31234-31244
21. Saifudeen Z., Du H., Dipp S., and El-Dahr S.S. The bradykinin type 2 receptor is a target for p53-mediated transcriptional activation. J. Biol. Chem. 275 (2000) 15557-15562
22. Marks J., Saifudeen Z., Dipp S., and El-Dahr S.S. Two functionally divergent p53-response elements in the rat bradykinin B2 receptor promoter. J. Biol. Chem. 278 (2003) 34158-34166
23. Shen B., Harrison-Bernard L.M., Fuller A.J., Vanderpool V., Saifudeen Z., and El-Dahr S.S. The bradykinin B2 receptor gene is a target of angiotensin II type 1 receptor signaling. J. Am. Soc. Nephrol. 18 (2007) 1140-1149
24. Saifudeen Z., Dipp S., Fan H., and El-Dahr S.S. Combinatorial control of the bradykinin B2 receptor promoter by p53, CREB, KLF-4 and CBP: implications for terminal nephron differentiation. Am. J. Physiol. Renal. Physiol. 288 (2005) F899-F909
25. Barlev N.A., Liu L., Chehab N.H., Mansfield K., Harris K.G., Halazonetis T.D., and Berger S.L. Acetylation of p53 activates transcription through recruitment of coactivators/histone acetyltransferases. Mol. Cell 8 (2001) 1243-1254
26. Murphy M., Ahn J., Walker K.K., Hoffman W.H., Evans R.M., Levine A.J., and George D.L. Transcriptional repression by wild-type p53 utilizes histone deacetylases, mediated by interaction with mSin3a. Genes Dev. 13 (1999) 2490-2501
27. Ho J., and Benchimol S. Transcriptional repression mediated by the p53 tumour suppressor. Cell Death. Differ. 10 (2003) 404-408
28. Hong T.M., Chen J.J., Peck K., Yang P.C., and Wu C.W. p53 amino acids 339-346 represent the minimal p53 repression domain. J. Biol. Chem. 276 (2001) 1510-1515
29. Farmer G., Friedlander P., Colgan J., Manley J.L., and Prives C. Transcriptional repression by p53 involves molecular interactions distinct from those with the TATA box binding protein. Nucleic Acids Res. 24 (1996) 4281-4288
30. Ko L.J., and Prives C. p53: puzzle and paradigm. Genes Dev 10 (1996) 1054-1072
31. 1/S-phase transition. Eur. J. Hum. Genet. 12 (2004) 433-440
32. Nishio S., Hatano M., Nagata M., Horie S., Koike T., Tokuhisa T., and Mochizuki T. Pkd1 regulates immortalized proliferation of renal tubular epithelial cells through p53 induction and JNK activation. J. Clin. Invest. 115 (2005) 910-918
33. Godley L.A., Kopp J.B., Eckhaus M., Paglino J.J., Owens J., and Varmus H.E. Wild-type p53 transgenic mice exhibit altered differentiation of the ureteric bud and possess small kidneys. Genes Dev. 10 (1996) 836-850